1999
A multisite phase III study of the safety and efficacy of a new manganese chloride‐based gastrointestinal contrast agent for MRI of the abdomen and pelvis
Small W, DeSimone‐Macchi D, Parker J, Sukerkar A, Hahn P, Rubin D, Zelch J, Kuhlman J, Outwater E, Weinreb J, Brown J, de Lange E, Woodward P, Arildsen R, Foster G, Runge V, Aisen A, Muroff L, Thoeni R, Parisky Y, Tanenbaum L, Totterman S, Herfkens R, Knudsen J, Laster R, Duerinckx A, Stillman A, Spritzer C, Saini S, Rofsky N, Bernardino M. A multisite phase III study of the safety and efficacy of a new manganese chloride‐based gastrointestinal contrast agent for MRI of the abdomen and pelvis. Journal Of Magnetic Resonance Imaging 1999, 10: 15-24. PMID: 10398973, DOI: 10.1002/(sici)1522-2586(199907)10:1<15::aid-jmri3>3.0.co;2-x.Peer-Reviewed Original ResearchConceptsGastrointestinal contrast agentAdverse eventsSite investigatorsGastrointestinal tract side effectsPatient diagnosisBlinded readersMore adverse eventsPhase III studyInflammatory bowel diseaseGroup of patientsPeptic ulcer diseaseML of placeboT2-weighted MRI scansMultisite clinical trialContrast agentsOral contrast agentAdditional diagnostic informationPlacebo patientsOral agentsIII studyBowel diseaseUlcer diseaseGastrointestinal pathologyLaboratory changesPhysical examination
1994
Safety and optimum concentration of a manganese chloride–based oral MR contrast agent
Bernardino M, Weinreb J, Mitchell D, Small W, Morris M. Safety and optimum concentration of a manganese chloride–based oral MR contrast agent. Journal Of Magnetic Resonance Imaging 1994, 4: 872-876. PMID: 7865949, DOI: 10.1002/jmri.1880040620.Peer-Reviewed Original Research